Intravasation, bloodstream survival, and extravasation — the five-step relay a single tumor cell must survive to seed a distant organ.
Metastasis begins with a physical breach. Tumor-associated blood vessels are structurally abnormal — leaky, poorly pericyte-covered, and often lined by tumor cells themselves (vascular mimicry). A carcinoma cell that has undergone partial epithelial-mesenchymal transition (EMT) degrades the basement membrane with matrix metalloproteinases (MMP-2, MMP-9) and squeezes between or through endothelial cells to enter the vessel lumen, joining the bloodstream as a newly minted circulating tumor cell (CTC).
Intravasation is rarely a solitary decision — it is the output of a genetic and microenvironmental program:
Epithelial-mesenchymal transition (EMT): • Loss of E-cadherin, gain of N-cadherin and vimentin • Transcription factors Snail, Slug, ZEB1/2, Twist drive the switch • Cells lose apical-basal polarity, gain front-back migratory polarity
Invasion of the stroma and vessel wall: • Proteolytic degradation of extracellular matrix by MMPs and cathepsins • Amoeboid or mesenchymal migration through matrix pores and tracks • Tumor-associated macrophages (TAMs) frequently escort invading cells and pre-clear a path — the CTC "invasion trio" of tumor cell, macrophage, and endothelial cell has been imaged directly at intravasation sites (TMEM, tumor microenvironment of metastasis)
Mechanics of the crossing itself: • Cell squeezes through inter-endothelial junctions (paracellular) or directly through an endothelial cell body (transcellular) • Nuclear deformability becomes rate-limiting: the nucleus is the stiffest organelle and must also pass through gaps often narrower than its resting diameter • Successful intravasation delivers the cell into fast-moving plasma, instantly exposing it to the mechanical and immunological gauntlet of the vasculature
Intravasation is a numbers game with a brutal filter already built in: of the millions of tumor cells a growing cancer can shed into local vasculature each day, only a minute fraction ever completes this first step — and, as later stages show, an even smaller fraction of those go on to matter clinically.
Once in the bloodstream, a CTC enters what is often described as the most hostile environment it will ever face. Turbulent flow and capillary-scale shear forces physically damage the cell, while natural killer (NK) cells, complement, and shear-induced anoikis (apoptosis from loss of matrix attachment) eliminate the overwhelming majority within hours. Estimates converge on a sobering figure: fewer than 1 in 10,000 CTCs that enter circulation ever survive to seed a metastasis — and many studies put the true efficiency far lower.
Multiple independent stresses compound against the CTC simultaneously:
Mechanical shear stress: • Turbulent flow through the heart and large vessels, plus narrow capillary passage, subjects the cell membrane and cytoskeleton to forces well above what a free-floating cell tolerates • Cells lacking a rigid cortical actin scaffold rupture or fragment within minutes
Anoikis: • Epithelial-derived cells are normally programmed to undergo apoptosis when detached from extracellular matrix • Only cells that have partially rewired survival signaling (e.g., via EMT, oncogenic RAS/AKT signaling) resist this default death program long enough to matter
Immune surveillance: • NK cells recognize and lyse CTCs lacking self MHC-I display or bearing stress ligands • Complement-mediated lysis and neutrophil-derived reactive oxygen species add further attrition • Platelets can paradoxically help a CTC survive by coating it (platelet cloaking), physically shielding it from NK recognition and providing pro-survival TGF-β signaling — one of the few pro-survival factors in an otherwise lethal environment
CTC clusters vs. singles: • Tumor cells that intravasate as multicellular clusters (sometimes escorted by neutrophils) show dramatically higher survival and metastatic efficiency than single CTCs, despite being rarer • Clusters resist anoikis via cell-cell contacts and present a smaller relative surface area to shear and immune attack
This stage is the single largest bottleneck in the entire cascade. If intravasation is the entry fee, circulation is the toll booth that turns most travelers away — survival here, not entry, is what ultimately gates how rare successful metastasis is.
A CTC that survives circulation eventually stops moving — not by choice, but because it physically cannot continue. Most capillaries are 5–10 µm in diameter, narrower than a 12–25 µm CTC, so simple size mismatch mechanically traps many cells at their first narrow passage. Others arrest through active adhesion: selectins and integrins on the endothelial surface engage ligands on the CTC in a rolling-then-sticking sequence borrowed directly from the leukocyte extravasation playbook.
Two arrest modes, not mutually exclusive:
Mechanical trapping: • The CTC simply cannot fit through the next capillary branch point and lodges in place • Especially relevant for the lung (first capillary bed downstream of most venous drainage) and liver (portal circulation) • Requires no specific molecular recognition — a purely physical filter
Adhesive arrest: • E-selectin and P-selectin on activated/inflamed endothelium engage sialylated glycoprotein ligands on the CTC surface, producing a rolling motion that slows the cell • Firm arrest follows via integrin-ICAM/VCAM interactions once rolling velocity drops enough for bond formation • This mirrors leukocyte homing almost exactly — metastasis co-opts an ancient immune trafficking mechanism
Organotropism ("seed and soil"): • Stephen Paget's 1889 hypothesis holds up remarkably well: metastatic organ preference is not random but reflects compatibility between circulating tumor cells ("seed") and the receptive microenvironment of specific organs ("soil") • Tumor-derived exosomes can pre-condition distant organs before CTCs even arrive, forming a "pre-metastatic niche" that upregulates the very adhesion molecules that will later capture arriving CTCs • Breast cancer favors bone, lung, liver, brain; colorectal cancer drains preferentially to liver; this pattern reflects both vascular anatomy and molecular compatibility
Arrest is not the finish line — it is a fragile foothold. An arrested CTC is still fully exposed to shear at the vessel wall and to any patrolling immune cells, and platelet cloaking or rapid extravasation is often what determines whether this foothold becomes permanent.
Extravasation is intravasation run in reverse, at the destination rather than the origin. The arrested CTC destabilizes endothelial cell-cell junctions, squeezes through (or between) endothelial cells via trans-endothelial migration, and enters the surrounding organ parenchyma — leaving the vasculature entirely and becoming a disseminated tumor cell (DTC) in the truest sense.
Extravasation requires the CTC to actively remodel the very barrier that normally keeps blood contents contained:
Junction disruption: • Tumor-secreted VEGF increases vascular permeability and loosens VE-cadherin-based adherens junctions • ANGPTL4, often induced by TGF-β signaling in the primary tumor, specifically disrupts endothelial cell-cell junctions at distant sites, priming them for CTC passage • Some CTCs additionally secrete pro-inflammatory cytokines that recruit neutrophils, which release proteases that further loosen the barrier
The crossing: • Paracellular route: CTC squeezes through the junction between two endothelial cells • Transcellular route: CTC punches directly through an individual endothelial cell body • Pseudopodial protrusions probe the abluminal (tissue-facing) side before the cell body follows, analogous to the invasive protrusions used during intravasation
After crossing: • The cell now sits in the distant organ's extracellular matrix, physically separated from blood flow • It is here that the next branch point in the cascade is decided: whether the cell can establish itself as a growing lesion, or whether it stalls
Extravasation and intravasation use overlapping molecular machinery, which is why some anti-metastatic strategies (e.g., targeting VEGF signaling or endothelial junction integrity) are explored for relevance at both ends of the cascade.
Reaching distant tissue is not the same as succeeding there. A disseminated tumor cell (DTC) now faces a foreign microenvironment lacking the growth factors, stroma, and vasculature of its tissue of origin. Most DTCs never proliferate; many die outright, and a substantial fraction instead enter a reversible, non-dividing dormant state — sometimes for years or decades — before a smaller number eventually reactivate and expand into a clinically detectable metastatic colony.
The colonization decision is governed by a balance of cell-intrinsic and microenvironmental signals:
Dormancy (growth arrest): • Cells enter a quiescent, largely G0-like state, often triggered by an unfavorable "soil" — insufficient angiogenic support, restrictive extracellular matrix (e.g., dormancy-inducing thrombospondin-1), or active immune surveillance that holds the DTC population in check without eliminating it (immune equilibrium) • Single dormant DTCs and small dormant micrometastases (angiogenically inert, growth balanced by apoptosis) are both described • Dormancy is clinically invisible: standard imaging cannot detect these cells, which is why relapse can occur long after apparent cure
Active colonization: • Requires the DTC (or its progeny) to acquire an angiogenic switch — recruiting new blood vessels once the lesion outgrows passive diffusion of oxygen and nutrients • Requires co-option or remodeling of the local stroma into a supportive niche, often recruiting mesenchymal and immune cells that become complicit in tumor growth • Requires continued evasion of adaptive and innate immunity as the lesion grows past the size where it can evade detection passively
Reactivation from dormancy: • Aging of the niche, chronic inflammation, tissue injury/repair signaling, and immunosenescence have all been implicated in tipping a stable dormant DTC population toward renewed proliferation • Once reactivated, growth can proceed rapidly, which is part of why late relapses can appear clinically aggressive despite years of prior dormancy
The dormancy-vs-colonization fork is the reason metastatic disease can resurface long after a primary tumor is treated: dormant disseminated cells are a real, biologically distinct reservoir of risk — not simply "missed" cells, but cells actively held in a non-growing state until the balance of signals shifts.